Esketamine nasal spray reduces depressive symptoms in two phase 3 studies

This article was originally published here

The ASPIRE I and II trials evaluated the efficacy and safety of esketamine nasal spray in 465 patients with the moderate-to-severe major depressive disorder who have active suicidal

The post Esketamine nasal spray reduces depressive symptoms in two phase 3 studies appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply